title: Effect of mifepristone on abortion access in the United States.
abstract: OBJECTIVE
  To examine the pattern of mifepristone uptake in the United States and whether the introduction of this drug has facilitated access to abortion services.
  
  
  METHODS
  Using data from a national census of abortion providers and from the U.S. distributor of mifepristone, we assessed the number and proportion of abortions performed using mifepristone, the distribution of mifepristone providers by provider type and medical specialty, and the geographic distribution of mifepristone and surgical providers.
  
  
  RESULTS
  The number of mifepristone providers increased from 208 in the last 2 months of 2000 to 700 in 2001, the first full year of availability, and to 902 in 2007. Some 158,000 mifepristone abortions were performed in 2007, representing an estimated 14% of all abortions and 21% of eligible early abortions. Physicians represented 51% of mifepristone providers but accounted for just 11% of abortions; most were obstetrician-gynecologists. The proportion of abortions in each state performed using mifepristone ranged from 0% to 80%. Most mifepristone abortions were performed at or near facilities that also provided surgical abortion. Only five mifepristone-only providers of 10 or more abortions were located farther than 50 miles from any surgical provider of 400 or more abortions.
  
  
  CONCLUSIONS
  Mifepristone has become an integral part of abortion provision in the United States and likely has contributed to a trend toward very early abortions. However, expectations that approval of mifepristone would result in a wider range of providers offering abortion have not yet been met, and mifepristone has not brought a major improvement in the geographic availability of abortion.
  
  
  METHODS
  III.
authors.affiliation: From the Guttmacher Institute, New York, New York.
authors.forename: Lawrence B
authors.initials: LB
authors.lastname: Finer
authors.forename: Junhow
authors.initials: J
authors.lastname: Wei
mesh_terms: D000021:Abortifacient Agents, Steroidal; D000028:Abortion, Induced / Q000706:statistics & numerical data*; D017277:Drug Approval; D004363:Drug Utilization; D005260:Female; D006297:Health Services Accessibility / Q000706:statistics & numerical data*; D006801:Humans; D015735:Mifepristone; D011247:Pregnancy; D014481:United States
chemical_list: D000021:Abortifacient Agents, Steroidal; D015735:Mifepristone
references.citation: Beal MW, Simmonds K. Clinical uses of mifepristone: an update for women’s health practitioners. J Midwifery Womens Health 2002;47:451–60.
references.citation: Clark WH, Hassoun D, Gemzell-Danielsson K, Fiala C, Winikoff B. Home use of two doses of misoprostol after mifepristone for medical abortion: a pilot study in Sweden and France. Eur J Contracept Reprod Health Care 2005;10:184–91.
references.citation: El-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995;332:983–7.
references.citation: Hamoda H, Ashok PW, Flett GM, Templeton A. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG 2005;112:1102–8.
references.citation: Hamoda H, Ashok PW, Flett GM, Templeton A. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation. Hum Reprod 2005;20:2348–54.
references.citation: Marions L. Mifepristone dose in the regimen with misoprostol for medical abortion. Contraception 2006;74:21–5.
references.citation: Schaff E. Evidence for shortening the time interval of prostaglandin after mifepristone for medical abortion. Contraception 2006;74:42–4.
references.citation: Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception 2002;66:247–50.
references.citation: Henshaw SK, Finer LB. The accessibility of abortion services in the United States, 2001. Perspect Sex Reprod Health 2003;35:16–24.
references.citation: Winikoff B, Ellertson C, Elul B, Sivin I. Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol. Results of a large multicenter trial in the United States. Mifepristone Clinical Trials Group. Arch Fam Med 1998;7:360–6.
references.citation: Jensen JT, Harvey SM, Beckman LJ. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study. Am J Obstet Gynecol 2000;182:1292–9.
references.citation: Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998;338:1241–7.
references.citation: Urquhart DR, Templeton AA, Shinewi F, Chapman M, Hawkins K, McGarry J, et al. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study–final results. Contraception 1997;55:1–5.
references.citation: Beal MW. Update on medication abortion. J Midwifery Womens Health 2007;52:23–30.
references.citation: Henderson JT, Hwang AC, Harper CC, Stewart FH. Safety of mifepristone abortions in clinical use. Contraception 2005;72:175–8.
references.citation: Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the literature. Contraception 2004;70:183–90.
references.citation: Sitruk-Ware R. Mifepristone and misoprostol sequential regimen side effects, complications and safety. Contraception 2006;74:48–55.
references.citation: Joffe C. Medical abortion in social context. Am J Obstet Gynecol 2000;183:S10–5.
references.citation: Leeman L, Asaria S, Espey E, Ogburn J, Gopman S, Barnett S. Can mifepristone medication abortion be successfully integrated into medical practices that do not offer surgical abortion? Contraception 2007;76:96–100.
references.citation: Jones RK, Zolna MR, Henshaw SK, Finer LB. Abortion in the United States: incidence and access to services, 2005. Perspect Sex Reprod Health 2008;40:6–16.
references.citation: Strauss LT, Gamble SB, Parker WY, Cook DA, Zane SB, Hamdan S. Abortion surveillance–United States, 2004. MMWR Surveill Summ 2007;56:1–33.
references.citation: Henshaw SK, Kost K. Trends in the characteristics of women obtaining abortions, 1974 to 2004. New York (NY): Guttmacher Institute; 2008.
references.citation: Child TJ, Thomas J, Rees M, MacKenzie IZ. A comparative study of surgical and medical procedures: 932 pregnancy terminations up to 63 days gestation. Hum Reprod 2001;16:67–71.
references.citation: Hamoda H, Ashok PW, Flett GM, Templeton A. Medical abortion at 9-13 weeks’ gestation: a review of 1076 consecutive cases. Contraception 2005;71:327–32.
references.citation: Jones RK, Henshaw SK. Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Perspect Sex Reprod Health 2002;34:154–61.
references.citation: Rosing MA, Archbald CD. The knowledge, acceptability, and use of misoprostol for self-induced medical abortion in an urban US population. J Am Med Womens Assoc 2000;55:183–5.
references.citation: Dehlendorf CE, Grumbach K. Medical liability insurance as a barrier to the provision of abortion services in family medicine. Am J Public Health 2008;98:1770–4.
references.citation: National Abortion Federation. Timeline of work to enhance the role of certified nurse-midwives (CNMs), nurse practitioners (NPs), and physician assistants (PAs) in abortion care. Washington (DC): National Abortion Federation; 2006.